Melphalan Tillomed

Melphalan, the active ingredient in Melphalan Tillomed, is an alkylating agent presented as a sterile injectable solution for intravenous use. It treats multiple myeloma, ovarian cancer, malignant melanoma and other solid tumors in adult patients.

GNH USA supplies Melphalan Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Melphalan is used in chemotherapy regimens targeting malignant cells of specific tumor types.

- Multiple myeloma: reduces malignant plasma‑cell proliferation and improves survival. - Ovarian cancer: incorporated into combination protocols to control tumor growth. - Malignant melanoma: administered in advanced‑disease regimens to achieve tumor regression. - Other solid tumors: added to treatment plans for various solid malignancies to enhance cytotoxic effect.

Melphalan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset frequently reported. - Fatigue: persistent tiredness during treatment. - Myelosuppression: decreased blood cell counts leading to anemia, neutropenia, or thrombocytopenia. - Alopecia: hair loss affecting scalp and body hair.

Serious or Rare Side Effects: - Secondary malignancies: risk of developing new cancers. - Severe infection: due to profound neutropenia. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Renal impairment: reduced kidney function.

When using Melphalan, clinicians should observe several safety measures to minimize risks.

- Monitor blood counts: perform regular CBC to detect myelosuppression. - Assess organ function: evaluate hepatic and renal function before each cycle. - Avoid in active infection: postpone treatment if severe infection is present. - Use antiemetics: prophylactic medication reduces nausea and vomiting. - Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss with specialist. - Store at ambient temperature: keep below 25 °C, in original container, protect from moisture and light.

Melphalan can interact with other medicines, altering its efficacy or toxicity.

Major Interactions (Avoid): - CYP450 inducers: drugs such as rifampin may reduce melphalan exposure. - Live vaccines: concurrent use can increase risk of infection.

Moderate Interactions (Monitor Closely): - Anticoagulants: enhanced bleeding risk; monitor INR/PT. - Nephrotoxic agents: concurrent use may worsen renal impairment. - Other myelosuppressive chemotherapy: additive bone‑marrow suppression; adjust dosing. - Allopurinol: may increase melphalan plasma levels; monitor toxicity.